SRZN
Surrozen, Inc./de Health Care Biological Products, (No Diagnostic Substances) Russell 3000
$29.04Close
$283.9MMarket cap
$16.16 – $33.6852-week range
Nov 6, 2026Next report
Highlights
Strengths
- Volume drying up last 10 days 43% under the 50-day average
Cautions
- Earnings shrinking EPS −53% year on year
- Results soon Nov 6, 2026, in 5 days
- Financial distress Altman Z″ in the distress zone
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
14%
1wk
up 14.0%
price change
1mo
down 9.8%
price change
12-month return
up 31%
total, dividends included
F-score
—
— Not assessed
Altman Z
-7.26
Elevated risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
—
price / book
Earnings yield
down 21.6%
EBIT / enterprise value
Cheaper than
5%
of the market · expensive
Revenue growth
down 67%
year on year
EPS growth
down 53%
latest quarter
Sales growth
up 409%
latest quarter · +0 pts
ROE
—
return on equity
Free cash margin
down 874%
-$30.4M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Trade setup
ATR%
8.6%
$2.49 a day · 2×ATR $24.06
RS
—
vs the universe
Trend
—
trend template
Relative volume
—
vs 50-day average
Up/down volume
—
50 sessions
Implied move
—
no option chain · report Nov 6, 2026
Contractions
2
38% → 29%
Pivot
$30.97
6.2% below
Volume dry-up
0.6×
10 vs 50 sessions
Screen verdict
Did not qualify for any screen.
Warning signs
- Liabilities exceed assets Shareholders' equity is negative at -$187.8M as of Dec 31, 2025. What is left for shareholders after creditors is, on the balance sheet, less than nothing.
- Bankruptcy model reads distressed The Altman score sits inside the range historically associated with financial distress. It is used here only to exclude, never to rank, and it is a statistical band rather than a prediction about this company.
- Shareholders diluted The share count rose 199.7% over the year, from 3m to 10m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
- Revenue shrinking Revenue fell 67.4% over the year, from $10.7M to $3.5M.
Last reported
Oct 20, 2026
Last shock
Oct 12, 2026-17% in one session1.8× volumeno filing matched+17% since
Financials
- Net -6961%
- Free cash -874%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | — | $0 | $12.5M | $0 | $10.7M | $3.5M |
| Operating income | -$32.8M | -$54.4M | -$44.3M | -$45.8M | -$25.5M | -$42.1M |
| Net income | -$32.7M | -$54.6M | -$36.0M | -$43.0M | -$63.6M | -$242.0M |
| Net margin | — | — | -288% | — | -597% | -6961% |
| Earnings per share | — | -$2,213.46 | -$15,559.20 | -$21,329.04 | -$21,672.01 | -$32,365.07 |
| Free cash flow | -$30.0M | -$50.1M | -$44.9M | -$40.8M | -$17.7M | -$30.4M |
| Free cash margin | — | — | -359% | — | -166% | -874% |
| Cash | $35.0M | $33.1M | $24.7M | $36.0M | $34.6M | $89.2M |
| Shareholders' equity | $47.3M | $109.7M | $76.0M | $37.9M | -$21.4M | -$187.8M |
| Shares outstanding | 18.26m | 35.03m | 2.01m | 2.06m | 3.26m | 9.78m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 6, 2026 | Quarterly ↗ | Jun 30, 2026 | 37d |
| May 6, 2026 | Quarterly ↗ | Mar 31, 2026 | 36d |
| Mar 23, 2026 | Annual ↗ | Dec 31, 2025 | 82d |
| Nov 7, 2025 | Quarterly ↗ | Sep 30, 2025 | 38d |
| Aug 8, 2025 | Quarterly ↗ | Jun 30, 2025 | 39d |
| May 9, 2025 | Quarterly ↗ | Mar 31, 2025 | 39d |
| Mar 31, 2025 | Annual ↗ | Dec 31, 2024 | 90d |
| Nov 6, 2024 | Quarterly ↗ | Sep 30, 2024 | 37d |
| Aug 12, 2024 | Quarterly ↗ | Jun 30, 2024 | 43d |
| May 8, 2024 | Quarterly ↗ | Mar 31, 2024 | 38d |
| Apr 10, 2024 | Annual ↗ | Dec 31, 2023 | 101d |
| Nov 8, 2023 | Quarterly ↗ | Sep 30, 2023 | 39d |
Current reports
| Filed | Disclosed |
|---|---|
| Oct 20, 2026 | Results · Unregistered share sale ↗ |
| Oct 2, 2026 | Other events ↗ |
| Aug 6, 2026 | Results ↗ |
| May 14, 2026 | Shareholder vote ↗ |
| May 6, 2026 | Results ↗ |
| Mar 23, 2026 | Results ↗ |
| Jan 30, 2026 | Director or officer change ↗ |
| Nov 7, 2025 | Results · Director or officer change ↗ |
| Oct 17, 2025 | Agreement ended ↗ |
| Aug 29, 2025 | Material agreement ↗ |
| Aug 8, 2025 | Results ↗ |
| May 15, 2025 | Shareholder vote ↗ |